Related references
Note: Only part of the references are listed.Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy
Shahryar Khoshtinat Nikkhoi et al.
FRONTIERS IN IMMUNOLOGY (2023)
Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3
Antonio Arulanandam et al.
CELLS (2023)
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma
Satoko Kakiuchi-Kiyota et al.
LEUKEMIA (2022)
Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
Natalia Colomar-Carando et al.
CANCER IMMUNOLOGY RESEARCH (2022)
Effect of non-repetitive linker on in vitro and in vivo properties of an anti-VEGF scFv
Merve Arslan et al.
SCIENTIFIC REPORTS (2022)
Tim-3 Blockade Elicits Potent Anti-Multiple Myeloma Immunity of Natural Killer Cells
Wen Jiang et al.
FRONTIERS IN ONCOLOGY (2022)
CAR-NK cells for cancer immunotherapy: from bench to bedside
Leisheng Zhang et al.
BIOMARKER RESEARCH (2022)
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
Nina Lamers-Kok et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer
Feifei Li et al.
FRONTIERS IN IMMUNOLOGY (2022)
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial
Stephanie Sasse et al.
LEUKEMIA & LYMPHOMA (2022)
Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course
Mengjie Jiang et al.
FRONTIERS IN ONCOLOGY (2022)
Nonclinical Pharmacokinetics, Pharmacodynamics, and Translational Model of RO7297089, A Novel Anti-BCMA/CD16A Bispecific Tetravalent Antibody for the Treatment of Multiple Myeloma
Hao Cai et al.
AAPS JOURNAL (2022)
The journey of CAR-T therapy in hematological malignancies
Junru Lu et al.
MOLECULAR CANCER (2022)
Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers
Sheena Pinto et al.
TRENDS IN IMMUNOLOGY (2022)
Current Progress of CAR-NK Therapy in Cancer Treatment
Zhaojun Pang et al.
CANCERS (2022)
Affibody-Based BCMA x CD16 Dual Engagers for Activation of NK Cells Towards Multiple Myeloma
Kim Anh Giang et al.
BLOOD (2022)
Biological Characterization and Differential Gene Expression Analysis of CYT-338 NK Cell Engager (NKE) Against CD38 Expressing Tumors Including Multiple Myeloma (MM)
Liang Lin et al.
BLOOD (2022)
Tim-3 and PD-1 blocking cannot restore the functional properties of natural killer cells in early clinical stages of chronic lymphocytic leukemia: An in vitro study
Mojgan Astaneh et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2022)
KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity
Matthew D. Blunt et al.
JOURNAL OF IMMUNOLOGY (2022)
Natural killer cells in antitumour adoptive cell immunotherapy
Tamara J. Laskowski et al.
NATURE REVIEWS CANCER (2022)
Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell Engagers
Uwe Reusch et al.
ANTIBODIES (2022)
Review Article Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
Dain Moon et al.
IMMUNE NETWORK (2022)
NK cells and ILCs in tumor immunotherapy
Simona Sivori et al.
MOLECULAR ASPECTS OF MEDICINE (2021)
A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells
Upasana Sunil Arvindam et al.
LEUKEMIA (2021)
Human Placental CD34+-Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 (CYNK-101) in Combination with Daratumumab for Immunotherapy Against CD38 Expressing Hematological Malignancies
Irene Raitman et al.
BLOOD (2021)
Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement
Lukas Pekar et al.
JOURNAL OF IMMUNOLOGY (2021)
Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response
Adeline Raynaud et al.
ONCOIMMUNOLOGY (2021)
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Lucila N. Kerbauy et al.
CLINICAL CANCER RESEARCH (2021)
CAR-NK Cells: From Natural Basis to Design for Kill
Muhammad Babar Khawar et al.
FRONTIERS IN IMMUNOLOGY (2021)
Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor
Elisa C. Toffoli et al.
CANCERS (2021)
HEK293 Cell Line as a Platform to Produce Recombinant Proteins and Viral Vectors
Evan Tan et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)
A comprehensive comparison between camelid nanobodies and single chain variable fragments
Yasaman Asaadi et al.
BIOMARKER RESEARCH (2021)
Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2+1 Common Light Chain Antibody Architecture
Jan P. Bogen et al.
FRONTIERS IN IMMUNOLOGY (2021)
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas
Claudia Manuela Arnone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Bispecific Antibody Designed for Targeted NK Cell Activation and Functional Assessment for Biomedical Applications
Ah-Young Song et al.
ACS APPLIED MATERIALS & INTERFACES (2021)
Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+NK cells to target myeloid leukemia
Emily Chiu et al.
MOLECULAR THERAPY (2021)
A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer
Daniel A. Vallera et al.
CANCERS (2021)
Affecting HEK293 Cell Growth and Production Performance by Modifying the Expression of Specific Genes
Laura Abaandou et al.
CELLS (2021)
From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
Hui Lu et al.
FRONTIERS IN ONCOLOGY (2021)
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins
Marlena Surowka et al.
MABS (2021)
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors
Susanne Wingert et al.
MABS (2021)
Activating killer cell immunoglobulin-like receptors: Detection, function and therapeutic use
Matthew D. Blunt et al.
INTERNATIONAL JOURNAL OF IMMUNOGENETICS (2020)
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
Nina Shah et al.
LEUKEMIA (2020)
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Daixi Ren et al.
MOLECULAR CANCER (2020)
Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab
Lionel Rouge et al.
SCIENCE (2020)
Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics
Heliang Li et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma
Yang Wang et al.
JOURNAL OF IMMUNOTHERAPY (2020)
Understanding the Synergy of NKp46 and Co-Activating Signals in Various NK Cell Subpopulations: Paving the Way for More Successful NK-Cell-Based Immunotherapy
Loris Zamai et al.
CELLS (2020)
NKp30-A prospective target for new cancer immunotherapy strategies
Pedro F. Pinheiro et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
Kin Man Au et al.
SCIENCE ADVANCES (2020)
CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma
Fangkun Liu et al.
SCIENTIFIC REPORTS (2020)
Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo
Yu Kato et al.
IMMUNITY (2020)
CAR-NK cells: A promising cellular immunotherapy for cancer
Guozhu Xie et al.
EBIOMEDICINE (2020)
NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
Daniel A. Vallera et al.
CANCERS (2020)
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
Hilma J. van der Horst et al.
CANCERS (2020)
Functional Domain Order of an Anti-EGFR x Anti-CD16 Bispecific Diabody Involving NK Cell Activation
Atsushi Kuwahara et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
Ying Cheng et al.
CANCER BIOLOGY & MEDICINE (2020)
Targeting autopalmitoylation of TEAD transcription factors
Xu Wu
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2020)
Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats
Ami Miller et al.
MABS (2020)
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
Simona Sivori et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
The NKG2A immune checkpoint - a new direction in cancer immunotherapy
Benjamin C. Creelan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
CAR T-cells: costs, comparisons, and commentary
Annette E. Hay et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Mechanisms of natural killer cell-mediated cellular cytotoxicity
Isabel Prager et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2019)
TNF--induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer
Yujia Zheng et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Laurent Gauthier et al.
CELL (2019)
NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing
Isabel Prager et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
The Natural Cytotoxicity Receptors in Health and Disease
Alexander David Barrow et al.
FRONTIERS IN IMMUNOLOGY (2019)
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial
Martine Bagot et al.
LANCET ONCOLOGY (2019)
PD-L1 expression levels on tumor cells affect their immunosuppressive activity
Yang Zheng et al.
ONCOLOGY LETTERS (2019)
CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma
Jennifer Watkins-Yoon et al.
BLOOD (2019)
Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma
Haoyu Sun et al.
HEPATOLOGY (2019)
Immunogenicity of Protein Pharmaceuticals
Robert Dingman et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives
Cristiana Lo Nigro et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Design and Production of Bispecific Antibodies
Qiong Wang et al.
ANTIBODIES (2019)
Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL
Martin Felices et al.
BLOOD ADVANCES (2019)
Current Progress in CAR-T Cell Therapy for Solid Tumors
Shuo Ma et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)
Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo-Expanded Autologous NK Cells
Yufeng Wang et al.
CLINICAL CANCER RESEARCH (2018)
Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts
Ping-Pin Zheng et al.
DRUG DISCOVERY TODAY (2018)
Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells
Katja Srpan et al.
JOURNAL OF CELL BIOLOGY (2018)
The less-is-more in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity
Natasha A. Pereira et al.
MABS (2018)
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Qing Zhang et al.
NATURE IMMUNOLOGY (2018)
Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma
Francesco Ceppi et al.
TRANSFUSION (2018)
Bispecific antibodies: design, therapy, perspectives
Sergey E. Sedykh et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
Wing Keung Chan et al.
CANCER IMMUNOLOGY RESEARCH (2018)
NKG2D: A Master Regulator of Immune Cell Responsiveness
Felix M. Wensveen et al.
FRONTIERS IN IMMUNOLOGY (2018)
IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction
Nicholas J. W. Easom et al.
FRONTIERS IN IMMUNOLOGY (2018)
Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells
Hans H. Oberg et al.
FRONTIERS IN IMMUNOLOGY (2018)
CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity
Amelia Roman Aguilera et al.
ONCOIMMUNOLOGY (2018)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre et al.
CELL (2018)
Universal CARs, universal T cells, and universal CAR T cells
Juanjuan Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3
Dionysos Slaga et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Engineering IgG-Like Bispecific AntibodiesAn Overview
Simon Krah et al.
ANTIBODIES (2018)
Natural killer cells and other innate lymphoid cells in cancer
Laura Chiossone et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma
Thorsten Ross et al.
BLOOD (2018)
Targeting IL-2: an unexpected effect in treating immunological diseases
Congxiu Ye et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2018)
Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells
Hyun Don Yun et al.
BLOOD ADVANCES (2018)
The Broad Spectrum of Human Natural Killer Cell Diversity
Aharon G. Freud et al.
IMMUNITY (2017)
Tim-3 and its role in regulating anti-tumor immunity
Madhumita Das et al.
IMMUNOLOGICAL REVIEWS (2017)
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells
Thorsten Gantke et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2017)
Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
Jorg U. Schmohl et al.
CANCER RESEARCH AND TREATMENT (2017)
AFM26-A novel CD16A-directed bispecific TandAb targeting BCMA for multiple myeloma
Thorsten Gantke et al.
CANCER RESEARCH (2017)
Affibody molecules as engineered protein drugs
Fredrik Y. Frejd et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2017)
Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+Colorectal Cancer Cells
J. U. Schmohl et al.
TARGETED ONCOLOGY (2016)
B7H6-derived Peptides Trigger TNF-α-dependent Immunostimulatory Activity of Lymphocytic NK92-MI Cells
Mariana Phillips et al.
BIOPOLYMERS (2016)
Anti-EGFRvIII TandAbs recruiting either T or NK cells are highly specific and potent therapeutic antibody candidates for the treatment of EGFRvIII plus tumors
Kristina Ellwanger et al.
CANCER RESEARCH (2016)
Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
Dhifaf Sarhan et al.
CANCER RESEARCH (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
Relationship of NKG2C Copy Number with the Distribution of Distinct Cytomegalovirus-Induced Adaptive NK Cell Subsets
Aura Muntasell et al.
JOURNAL OF IMMUNOLOGY (2016)
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
Rizwan Romee et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
Reza Ghasemi et al.
NATURE COMMUNICATIONS (2016)
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
Stephen J. Blake et al.
CANCER DISCOVERY (2016)
Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker
Joerg U. Schmohl et al.
ONCOTARGET (2016)
Can we make a better match or mismatch with KIR genotyping?
Rohtesh S. Mehta et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
NKG2C+CD57+ Natural Killer Cell Expansion Parallels Cytomegalovirus-Specific CD8+ T Cell Evolution towards Senescence
John Heath et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
Phenotypic and Functional Dysregulated Blood NK cells in colorectal cancer Patients can Be activated by cetuximab Plus IL-2 or IL-15
Yamila Sol Rocca et al.
FRONTIERS IN IMMUNOLOGY (2016)
Features of Memory-Like and PD-1+ Human nK Cell Subsets
Mariella Della Chiesa et al.
FRONTIERS IN IMMUNOLOGY (2016)
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Xiuyan Wang et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
Trispecific Antibodies for Selective CD16A-Directed NK-Cell Engagement in Multiple Myeloma
Thorsten Gantke et al.
BLOOD (2016)
CD20 Tcb (RG6026), a Novel 2:1 T Cell Bispecific Antibody for the Treatment of B Cell Malignancies
Marina Bacac et al.
BLOOD (2016)
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
Achim Rothe et al.
BLOOD (2015)
Generation and Preclinical Characterization of an NKp80-Fc Fusion Protein for Redirected Cytolysis of Natural Killer (NK) Cells against Leukemia
Gang Deng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
CD160 is essential for NK-mediated IFN-γ production
Tony C. Tu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
DNAM-1 controls NK cell activation via an ITT-like motif
Zhanguang Zhang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Alternative molecular formats and therapeutic applications for bispecific antibodies
Christoph Spiess et al.
MOLECULAR IMMUNOLOGY (2015)
HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity
Matthias Peipp et al.
ONCOTARGET (2015)
Polyclonal expansion of NKG2C+ NK cells in TAP-deficient patients
Vivien Beziat et al.
FRONTIERS IN IMMUNOLOGY (2015)
B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape
Silvia Pesce et al.
ONCOIMMUNOLOGY (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
Engineering disulfide bonds within an antibody
Yoshihisa Hagihara et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2014)
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
Michelle K. Gleason et al.
BLOOD (2014)
Efficient generation of human natural killer cell lines by viral transformation
B. Vogel et al.
LEUKEMIA (2014)
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells
Uwe Reusch et al.
MABS (2014)
The immune synapse clears and excludes molecules above a size threshold
Adam N. R. Cartwright et al.
NATURE COMMUNICATIONS (2014)
Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
Eric O. Long et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
Rizwan Romee et al.
BLOOD (2013)
Heterodimeric Bispecific Single-Chain Variable-Fragment Antibodies Against EpCAM and CD16 Induce Effective Antibody-Dependent Cellular Cytotoxicity Against Human Carcinoma Cells
Daniel A. Vallera et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2013)
Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Andres Wiernik et al.
CLINICAL CANCER RESEARCH (2013)
Dynamics of NK cell interactions in vivo
Jacques Deguine et al.
IMMUNOLOGICAL REVIEWS (2013)
Membrane-Type 6 Matrix Metalloproteinase Regulates the Activation-Induced Downmodulation of CD16 in Human Primary NK Cells
Giovanna Peruzzi et al.
JOURNAL OF IMMUNOLOGY (2013)
Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies
Christoph Spiess et al.
NATURE BIOTECHNOLOGY (2013)
Matching cellular dimensions with molecular sizes
Michael Reth
NATURE IMMUNOLOGY (2013)
Strategies for the Production of Recombinant Protein in Escherichia coli
Gopal Jee Gopal et al.
PROTEIN JOURNAL (2013)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger et al.
BLOOD (2012)
The effect of antigen size on the immunogenicity of antigen presenting cell targeted DNA vaccine
Rong Jia et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2012)
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
Michelle K. Gleason et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Molecular mechanisms of Treg-mediated T cell suppression
Angelika Schmidt et al.
FRONTIERS IN IMMUNOLOGY (2012)
Evolving role of 2B4/CD244 in T and NK cell responses during virus infection
Stephen N. Waggoner et al.
FRONTIERS IN IMMUNOLOGY (2012)
Bi-Specific Killer Cell Engagers (BiKEs) Signaling Through CD16 and Targeting CD33 (CD16 x CD33), Triggers Natural Killer (NK) Cell Cytotoxic and Cytokine Production Against Refractory Acute Myeloid Leukemia (AML)
Andres Wiernik et al.
BLOOD (2012)
Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma
Sophia Platonova et al.
CANCER RESEARCH (2011)
Strategies for extended serum half-life of protein therapeutics
Roland E. Kontermann
CURRENT OPINION IN BIOTECHNOLOGY (2011)
CD160: A unique activating NK cell receptor
Philippe Le Bouteiller et al.
IMMUNOLOGY LETTERS (2011)
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
Emilie Mamessier et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Cutting Edge: NKp80 Uses an Atypical Hemi-ITAM To Trigger NK Cytotoxicity
Kevin M. Dennehy et al.
JOURNAL OF IMMUNOLOGY (2011)
Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules
Nina Kronqvist et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2011)
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects APPLICATIONS TO BISPECIFIC MOLECULES AND MONOVALENT IgG
Kannan Gunasekaran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B
Ying Ju et al.
JOURNAL OF HEPATOLOGY (2010)
SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies
Jonathan H. Davis et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Martin F. Bachmann et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Strategies to Extend Plasma Half-Lives of Recombinant Antibodies
Roland E. Kontermann
BIODRUGS (2009)
Engineering peptide linkers for scFv immunosensors
Zhihong Shen et al.
ANALYTICAL CHEMISTRY (2008)
The impact of PEGylation on biological therapies
Francesco M. Veronese et al.
BIODRUGS (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology
Bernard M. Tijink et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Targeting EGFR in colorectal cancer
Wells A. Messersmith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Formation and function of the lytic NK-cell immunological synapse
Jordan S. Orange
NATURE REVIEWS IMMUNOLOGY (2008)
Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin
Dafne Mueller et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The change of the scFv into the Fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies
Veronica Quintero-Hernandez et al.
MOLECULAR IMMUNOLOGY (2007)
CD56dimCD16+ NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases
B. Grzywacz et al.
LEUKEMIA (2007)
Selection and characterization of affibody ligands binding to Alzheimer amyloid β peptides
Caroline Gronwall et al.
JOURNAL OF BIOTECHNOLOGY (2007)
Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction
Cyril Fauriat et al.
BLOOD (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction
Stefan Welte et al.
NATURE IMMUNOLOGY (2006)
Tumor Imaging using a picomolar affinity HER2 binding affibody molecule
A Orlova et al.
CANCER RESEARCH (2006)
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
EP von Strandmann et al.
BLOOD (2006)
Soluble MICA in malignant diseases
S Holdenrieder et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion
YT Bryceson et al.
BLOOD (2006)
Engineering novel binding proteins from nonimmunoglobulin domains
HK Binz et al.
NATURE BIOTECHNOLOGY (2005)
Arf6:: a new player in FcγRIIIA lymphocyte-mediated cytotoxicity
R Galandrini et al.
BLOOD (2005)
The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure
D Garrity et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Immunogenicity of engineered antibodies
WYK Hwang et al.
METHODS (2005)
Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: Evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)
D Pende et al.
BLOOD (2005)
Rat NKp46 activates natural killer cell cytotoxicity and is associated with FcεRIγ and CD3ζ
IH Westgaard et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2004)
Cutting edge: Engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset
A Barakonyi et al.
JOURNAL OF IMMUNOLOGY (2004)
Molecular dissection of 2134 signaling: Implications for signal transduction by SLAM-related receptors
RY Chen et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma
ES Doubrovina et al.
JOURNAL OF IMMUNOLOGY (2003)
Crystal structure of the human natural killer (NK) cell activating receptor NKp46 reveals structural relationship to other leukocyte receptor complex immunoreceptors
CE Foster et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway
DD Billadeau et al.
NATURE IMMUNOLOGY (2003)
The size of the synaptic cleft and distinct distributions of filamentous actin, ezrin, CD43, and CD45 at activating and inhibitory human NK cell immune synapses
FE McCann et al.
JOURNAL OF IMMUNOLOGY (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity
P Le Bouteiller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The role of the NKG2D immunoreceptor in immune cell activation and natural killing
AM Jamieson et al.
IMMUNITY (2002)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
UL16-Binding proteins, novel MHC class I-Related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells
CL Sutherland et al.
JOURNAL OF IMMUNOLOGY (2002)
X-linked lymphoproliferative disease: 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells
S Parolini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Crystal structure of the exctracellular domain of a human Fc gamma RIII
YH Zhang et al.
IMMUNITY (2000)